Abstract
The voltage-gated Cav1.2 calcium channels respond to membrane depolarization by increasing the membrane permeability to Ca2+, a major signal for cardiac muscle contraction, regulation of vascular tone and CREB-dependent transcriptional activation. CACNB2 is one of the four homologous genes coding for the auxiliary Cavβ subunits, which are important modulators of the Ca2+ channel activity. Five serious mental disorders - autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia, - and three major cardiovascular diseases - hypertension, heart failure and sudden cardiac death, - have recently been linked to the CACNB2 gene coding for the Cavβ2 subunits. Here I will focus on the Cavβ2-specific molecular determinant β2-CED as an emerging pharmacological target.
Keywords: Cav1.2 calcium channel, Cavβ subunits, CACNB2, heart failure, hypertension, mental disorders.
Current Molecular Pharmacology
Title:CACNB2: An Emerging Pharmacological Target for Hypertension, Heart Failure, Arrhythmia and Mental Disorders
Volume: 8
Author(s): Nikolai M. Soldatov
Affiliation:
Keywords: Cav1.2 calcium channel, Cavβ subunits, CACNB2, heart failure, hypertension, mental disorders.
Abstract: The voltage-gated Cav1.2 calcium channels respond to membrane depolarization by increasing the membrane permeability to Ca2+, a major signal for cardiac muscle contraction, regulation of vascular tone and CREB-dependent transcriptional activation. CACNB2 is one of the four homologous genes coding for the auxiliary Cavβ subunits, which are important modulators of the Ca2+ channel activity. Five serious mental disorders - autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia, - and three major cardiovascular diseases - hypertension, heart failure and sudden cardiac death, - have recently been linked to the CACNB2 gene coding for the Cavβ2 subunits. Here I will focus on the Cavβ2-specific molecular determinant β2-CED as an emerging pharmacological target.
Export Options
About this article
Cite this article as:
Soldatov M. Nikolai, CACNB2: An Emerging Pharmacological Target for Hypertension, Heart Failure, Arrhythmia and Mental Disorders, Current Molecular Pharmacology 2015; 8 (1) . https://dx.doi.org/10.2174/1874467208666150507093258
DOI https://dx.doi.org/10.2174/1874467208666150507093258 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Update on the Association of Protein Kinases with Cardiovascular Diseases
Current Pharmaceutical Design Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)
Current Vascular Pharmacology Nephrotoxicity Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Drug Safety Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology
Cardiovascular & Hematological Disorders-Drug Targets The Crosstalk between Gut Inflammation and Gastrointestinal Disorders During Acute Pancreatitis
Current Pharmaceutical Design Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Oxidative RNA Damage and Neurodegeneration
Current Medicinal Chemistry Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Insulinoma Case Admitted with Reactive Hypoglycemia Symptoms
Current Diabetes Reviews Novel Possible Pharmaceutical Research Tools: Stem Cells, Gene Delivery and their Combination
Current Pharmaceutical Design Lysosomotropic Drugs: Pharmacological Tools to Study Lysosomal Function
Current Drug Metabolism Catecholamines, Sympathetic Innervation and Immunity: Role in Experimental and Rheumatoid Arthritis
Letters in Drug Design & Discovery The Role of Bacteria and Viruses in Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Editorial [ Nuclear Receptors as Drug Discovery Targets Executive Editor: Sunil Nagpal ]
Mini-Reviews in Medicinal Chemistry Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction
Current Drug Targets First Autochthonous case of Emerged Zoonotic Cutaneous Leishmaniasis in Mazandaran Province, Northern Iran: kDNA-PCR Evidence Base
Infectious Disorders - Drug Targets Congestive Heart Failure: Pharmacological Agents and the Potential of BType Natriuretic Peptide
Current Medicinal Chemistry Lipids, Statins and Heart Failure: An Update
Current Pharmaceutical Design Recent Patents and Advances on Isolation and Cellular Therapy Applications of Mesenchymal Stem Cells from Human Umbilical Cord Whartons Jelly
Recent Patents on Regenerative Medicine Renal Innervation in Resistant Hypertension: A Review of Pathophysiology and Renal Denervation as Potential Treatment
Current Hypertension Reviews